Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

Z1252

Sigma-Aldrich

Zofenopril calcium

>98% (HPLC), powder

Synonym(s):

(4S)-1-[(2S)-3-(benzoylthio)-2-methyl-1-oxopropyl]-4-(phenylthio)-L-proline calcium salt

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C22H22NO4S2 · 0.5Ca
CAS Number:
81938-43-4
Molecular Weight:
448.58
MDL number:
MFCD11858294
UNSPSC Code:
12352200
PubChem Substance ID:
329831603

Quality Level

100

assay

>98% (HPLC)

form

powder

color

white to off-white

solubility

DMSO: >5 mg/mL

originator

Bristol-Myers Squibb

storage temp.

2-8°C

SMILES string

[Ca++].C[C@H](CSC(=O)c1ccccc1)C(=O)N2C[C@H](C[C@H]2C([O-])=O)Sc3ccccc3.C[C@H](CSC(=O)c4ccccc4)C(=O)N5C[C@H](C[C@H]5C([O-])=O)Sc6ccccc6

InChI

1S/2C22H23NO4S2.Ca/c2*1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17;/h2*2-11,15,18-19H,12-14H2,1H3,(H,25,26);/q;;+2/p-2/t2*15-,18+,19+;/m11./s1

InChI key

NSYUKKYYVFVMST-LETVYOFWSA-L

Biochem/physiol Actions

Zofenopril is a long-lasting, lipophilic ACE inhibitor. Zofenopril is also an inhibitor of PEPT2, the predominant peptide transporter in kidney and choroid plexus.
Zofenopril is an angiotensin-converting enzyme (ACE) inhibitor and a PEPT2 inhibitor.

Features and Benefits

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound is featured on the Angiotensin Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

pictograms

Environment
GHS09

signalword

Warning

hcodes

H410

Hazard Classifications

Aquatic Acute 1 - Aquatic Chronic 1

Storage Class

13 - Non Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000019083
0000019084
021M4705V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Giuseppe Sacco et al.
Vascular pharmacology, 50(5-6), 166-170 (2009-04-07)
The angiotensin converting enzyme inhibitor zofenopril has been shown to possess cardioprotective effects toward myocardial damage induced by chronic doxorubicin treatment in the rat. In the present study we have investigated the relationship between cardioprotection exerted by 2 angiotensin converting
Alessandra Del Fiorentino et al.
Journal of the renin-angiotensin-aldosterone system : JRAAS, 11(4), 243-247 (2010-08-28)
Angiotensin (Ang)II, the effector arm of the locally active renin-angiotensin system (RAS), modulates Tissue Factor (TF), the principal initiator of blood coagulation and a key promoter of atherothrombotic events. Consistent with that knowledge, previous data showed inhibitory properties of angiotensin-converting
Donatella Mutolo et al.
Journal of cardiovascular pharmacology and therapeutics, 15(4), 384-392 (2010-10-07)
Cough is the most common symptom reported by patients in a primary care setting and is one of the most frequent secondary effects recorded during treatment with angiotensin-converting enzyme (ACE) inhibitors. The aim of the current study was to analyze
Vittoria Carnicelli et al.
Molecular and cellular biochemistry, 352(1-2), 301-307 (2011-03-12)
We investigated whether acute and chronic administration of zofenopril, an angiotensin converting enzyme inhibitor, may modulate the expression of genes which are involved in the pathophysiology of myocardial ischemia and heart failure. We used an acute and a chronic model.
Cecilia Cialdai et al.
Naunyn-Schmiedeberg's archives of pharmacology, 382(5-6), 455-461 (2010-09-18)
Dry and persistent cough is one of the commonest side effects experienced by patients treated with angiotensin-converting enzyme (ACE) inhibitors for the therapy of hypertension and congestive heart failure. The present study investigated the effect of zofenopril and ramipril on
View All Related Papers

Articles

Discover Bioactive Small Molecules for ADME/Tox

Discover Bioactive Small Molecules for ADME/Tox

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service